Browsing ODA Open Digital Archive by Author "Røssevold, Andreas Hagen"
Now showing items 1-2 of 2
-
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials
Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Borgen, Elin; Schirmer, Cecilie; Gilje, Bjørnar; Garred, Øystein; Lømo, Jon; Stensland, Marius; Nordgård, Oddmund; Falk, Ragnhild Sørum; Ruud, Randi Margit; Russnes, Hege Elisabeth Giercksky; Kyte, Jon A; Naume, Bjørn (Peer reviewed; Journal article, 2024)Immune checkpoint inhibitors (ICIs) have been introduced in breast cancer (BC) treatment and better biomarkers are needed to predict benefit. Circulating tumor cells (CTCs) are prognostic in BC, but knowledge is limited ... -
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: A randomized phase 2b trial
Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Quaghebeur, Claire; Gilje, Bjørnar; Boge, Beate; Gombos, Andrea; Falk, Ragnhild Sørum; Ruud, Randi Margit; Julsrud, Lars; Garred, Øystein; Russnes, Hege Elisabeth Giercksky; Lereim, Ragnhild Reehorst; Chauhan, Sudhir Kumar; Lingjærde, Ole Christian; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Peer reviewed; Journal article, 2024)Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+ mBC). Doxorubicin and low- dose cyclophosphamide are reported to induce immune ...